Search scope:
排序: Display mode:
Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 139-149 doi: 10.1007/s11684-021-0835-8
Keywords: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia
Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen
Frontiers of Medicine 2021, Volume 15, Issue 3, Pages 347-371 doi: 10.1007/s11684-020-0821-6
Keywords: BCP-ALL subtypes translocation aneuploidy sequence mutations
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen
Frontiers of Medicine 2012, Volume 6, Issue 4, Pages 416-420 doi: 10.1007/s11684-012-0224-4
Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acutelymphoblastic leukemia (B-ALL).This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblasticleukemia with poor prognosis.
Keywords: acute lymphoblastic leukemia early T precursor prognosis
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia
Frontiers of Medicine 2022, Volume 16, Issue 3, Pages 442-458 doi: 10.1007/s11684-021-0877-y
Keywords: T-cell acute lymphoblastic leukemia HDAC inhibitor chidamide NOTCH1 MYC ubiquitination
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 689-700 doi: 10.1007/s11684-020-0759-8
Keywords: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
Frontiers of Medicine 2023, Volume 17, Issue 3, Pages 518-526 doi: 10.1007/s11684-022-0958-6
Keywords: acute lymphoblastic leukemia child venous thromboembolism epidemiology clinical characteristic risk
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia
Ching-Hon Pui
Frontiers of Medicine 2015, Volume 9, Issue 1, Pages 1-9 doi: 10.1007/s11684-015-0381-3
With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvementpatients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cellDeeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemiasuch as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic
Keywords: pharmacogenomics acute lymphoblastic leukemia genomics pharmacogenetics
Frontiers of Medicine 2022, Volume 16, Issue 2, Pages 285-294 doi: 10.1007/s11684-021-0843-8
Keywords: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 783-804 doi: 10.1007/s11684-021-0904-z
Keywords: CAR T cells hematological malignancies review
Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang
Engineering 2019, Volume 5, Issue 1, Pages 150-155 doi: 10.1016/j.eng.2018.12.006
Keywords: Donor-derived CD19-targeted T cell infusion Hematopoietic stem cell transplantation B cell acute lymphoblasticleukemia Minimal residual disease
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
Frontiers of Medicine 2022, Volume 16, Issue 5, Pages 815-826 doi: 10.1007/s11684-021-0891-0
Keywords: B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic
Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin
Frontiers of Medicine 2017, Volume 11, Issue 2, Pages 229-238 doi: 10.1007/s11684-017-0506-y
A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group foradult acute lymphoblastic leukemia (ALL).Fifty-eight (36 with haploidentical donor) patients underwent allogeneic hematopoietic stem cell transplantation
Keywords: Philadelphia chromosome acute lymphoblastic leukemia imatinib CALLG2008
Frontiers of Medicine 2023, Volume 17, Issue 4, Pages 699-713 doi: 10.1007/s11684-022-0972-8
Keywords: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment
Yuting Tan,Han Liu,Saijuan Chen
Frontiers of Medicine 2015, Volume 9, Issue 4, Pages 412-420 doi: 10.1007/s11684-015-0423-x
Genetic mutations are considered to drive the development of acute myeloid leukemia (AML).mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia
Keywords: preleukemic stem cell acute myeloid leukemia relapse DNMT3A
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu, Jianhong Chu, Depei Wu
Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 701-710 doi: 10.1007/s11684-020-0763-z
Keywords: acute myeloid leukemia CAR T immunotherapy
Title Author Date Type Operation
characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cellacute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
Journal Article
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia
Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen
Journal Article
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
Meilin Ma, Xiang Wang, Jingyan Tang, Huiliang Xue, Jing Chen, Ci Pan, Hua Jiang, Shuhong Shen
Journal Article
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia
Journal Article
Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese
Journal Article
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia
Ching-Hon Pui
Journal Article
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients
Journal Article
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Journal Article
Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation
Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang
Journal Article
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
Journal Article
imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acutelymphoblastic leukemia
Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin
Journal Article
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma
Journal Article
Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse
Yuting Tan,Han Liu,Saijuan Chen
Journal Article